A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity

Trenk, D; Stone, GW; Gawaz, M; Kastrati, A; Angiolillo, DJ; Müller, U; Richardt, G; Jakubowski, JA; Neumann, FJ

doi:10.1016/j.jacc.2012.02.026

journal article

Titel:: A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
Dokumenttyp:: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Article
Autor(en):: Trenk, D; Stone, GW; Gawaz, M; Kastrati, A; Angiolillo, DJ; Müller, U; Richardt, G; Jakubowski, JA; Neumann, FJ
Abstract:: This study sought to investigate the efficacy, safety, and antiplatelet effect of prasugrel as compared with clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after elective percutaneous coronary intervention (PCI).The extent to which prasugrel can correct HTPR and improve clinical outcomes in patients undergoing elective PCI is unknown.Stable coronary artery disease (CAD) patients with HTPR (>208 P2Y(12) reaction units [PRU] by the VerifyNow test) after elective PCI with at least 1 drug-eluting stent (DES) were randomly assigned to either prasugrel 10 mg daily or clopidogrel 75 mg daily. Platelet reactivity of the patients on the study drug was reassessed at 3 and 6 months. The study was stopped prematurely for futility because of a lower than expected incidence of the primary endpoint.In 212 patients assigned to prasugrel, PRU decreased from 245 (225 to 273) (median [interquartile range]) at baseline to 80 (42 to 124) at 3 months, whereas in 211 patients assigned to clopidogrel, PRU decreased from 249 (225 to 277) to 241 (194 to 275) (p < 0.001 vs. prasugrel). The primary efficacy endpoint of cardiac death or myocardial infarction at 6 months occurred in no patient on prasugrel versus 1 on clopidogrel. The primary safety endpoint of non-coronary artery bypass graft Thrombolysis In Myocardial Infarction major bleeding at 6 months occurred in 3 patients (1.4%) on prasugrel versus 1 (0.5%) on clopidogrel.Switching from clopidogrel to prasugrel in patients with HTPR afforded effective platelet inhibition. However, given the low rate of adverse ischemic events after PCI with contemporary DES in stable CAD, the clinical utility of this strategy could not be demonstrated.
Zeitschriftentitel:: J Am Coll Cardiol
Jahr:: 2012
Band / Volume:: 59
Heft / Issue:: 24
Seitenangaben Beitrag:: 2159-64
Sprache:: eng
Volltext / DOI:: doi:10.1016/j.jacc.2012.02.026
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/22520250
Print-ISSN:: 0735-1097
TUM Einrichtung:: I. Medizinische Klinik und Poliklinik (Kardiologie)
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Innere Medizin I, Kardiologie (Prof. Laugwitz)2012